ISPE’s Post

Have you seen the agenda for the Hit ID Summit? See the full event guide via the website here: https://ter.li/ohvqeg Here's a peak at the highlights: 💡 - Tailoring the available, different, screening approaches and match them to your specific targets 💡 - Taking cross learnings from peers and case study presentations to inform hit strategy 💡 - Leveraging DEL, HTS, AI, FBDD, to give a more holistic and detailed picture of how to optimise hit screening With Expert Speakers: Andrew Zhang, Director, Chemical Biology, AstraZeneca Bakhos Tannous, Head, NeuroOncology Discovery, AstraZeneca Christopher Barbieri, Associate Director, Molecular Pharmacology & Screening Technologies, Bristol Myers Squibb Brian Dill, Director, Proteomics, BPGbio, Inc. Yifan Song, Chief Scientific Officer, Cyrus Biotechnology Karenbir Pahil, Investigatior, GSK Spurti Akki, PhD, Senior Scientist, insitro Pat Brady, Senior Director, Computational Chemistry, Kymera Therapeutics Oscar Huang, Associate Director, Biophysics, Lyterian Therapeutics Fabien Vincent, Research Fellow, Pfizer Tim Foley, Lab Head, DNA-Encoded Library, Selection & Pharmacology, Pfizer Woody Sherman, Chief Innovation Officer, Psivant Therapeutics Scott Barraza, Group Leader, Early Discovery Therapeutics, PTC Therapeutics, Inc. Shruthi Bharadwaj, Ph.D, Global Lead, Digital & Analytics, Sanofi Brent Martin, Vice President, Chemical Biology, Scorpion Therapeutics Taosheng Chen, Head of High Throughput Biology, St Jude Children's Hospital Nii Ayi Hesse, Senior Research Scientist, The Francis Crick Institute Rachael Jetson, Senior Director, Lead Discovery, Valo Health Steven Fesik, Professor, Biochemistry, Pharmacology, & Chemistry, Vanderbilt University #hitidentification #hitid #hitscreening #hitfinding #hittolead #drugdiscovery #discovery #undruggable #drugdevelopment #HTS #DEL #dnaencodedlibraries #AI #chemicallibraries

🌟 What's New in Drug Discovery? Let's Dive In! 🌟 Hello, fellow drug discovery aficionados! The world of drug discovery is always buzzing with new challenges and innovations. Let’s talk about what’s currently shaping our industry. 🔬 Key Needs in Drug Discovery: - Cutting-Edge Technology: What new tools are revolutionizing your lab work? - Collaboration: How do we build stronger partnerships for faster breakthroughs? - Regulatory Hurdles: What’s the best way to navigate the ever-changing landscape? 💡 Emerging Trends: - AI and Big Data: How are these tools enhancing our research capabilities? - Personalized Medicine: What strides are we making in tailoring treatments? - Sustainability: How are we making our processes greener? 💬 Your Thoughts? I’d love to hear from you! What’s the biggest challenge you’re facing in drug discovery today? What innovations are you most excited about? Drop a comment or send me a message—let’s get a conversation going! 🚀 Let's Connect! By the way, if you're as passionate about these topics as I am, we’ve got an incredible opportunity to dive deeper. The 17th DDSS Summit in Munich on October 23-24 will be a fantastic place to meet, learn, and share ideas. Feel free to message me for more details! 🔗 https://lnkd.in/dSmySJWC #DrugDiscovery #Pharma #HealthcareInnovation #AIinHealthcare #PrecisionMedicine #Sustainability #Networking #DDSSSummit

Calluna Pharma is attending Bio€quity Europe conference, taking place 12-14 May, organized by BioCentury Inc. and EBD Group. Our CEO John Montana is going to be in San Sebastian next week for one of Europe’s top experiences for CEOS and investors to network, partner and discuss key issues facing the biotech industry. This is an opportunity to learn more about how to reach discussion stage with investors, discover 100+ emerging biotechs, and dive into European biotech trends. Find out more, and join us here: https://lnkd.in/dzunkQc #Biotech #Pharma #VentureCapital #BioEquityEurope #BioEquity

If you are at Interphex tomorrow, Tuesday April 16th , make sure you stop by #booth3506 and let’s discuss what’s new with #TheBakerCompany

𝙄𝙣𝙩𝙧𝙤𝙙𝙪𝙘𝙞𝙣𝙜 𝙩𝙝𝙚 𝙄𝙣𝙖𝙪𝙜𝙪𝙧𝙖𝙡 𝙋𝙤𝙧𝙩𝙛𝙤𝙡𝙞𝙤 𝙎𝙩𝙧𝙖𝙩𝙚𝙜𝙮 & 𝘿𝙚𝙘𝙞𝙨𝙞𝙤𝙣 𝙈𝙖𝙠𝙞𝙣𝙜 𝙛𝙤𝙧 𝘽𝙞𝙤𝙥𝙝𝙖𝙧𝙢𝙖 𝙎𝙪𝙢𝙢𝙞𝙩! Join us in Boston, MA, this November 20-21 for a transformative event tailored for leaders in portfolio strategy within the biopharma industry. This summit offers a unique opportunity to connect with over 60 leaders from top pharma and biotech companies, all focused on enhancing portfolio strategies. You'll gain expert insights, forge valuable partnerships, and foster cross-functional collaboration in an intimate setting designed for impactful networking. In today's rapidly evolving biopharma landscape, staying ahead is more critical than ever. By attending, you'll equip yourself to make informed decisions, mitigate risks, align stakeholders, and drive sustainable portfolio growth. Don't miss out on this essential event to navigate the challenges and seize the opportunities in the biopharma market. Download the newly released event guide today to explore the comprehensive agenda and 19+ world-class speakers joining us: https://ter.li/7b0sum #DecisionMaking #Biopharma #BioPharmaSummit #PortfolioStrategy #PharmaLeadership #StrategicDecisions #BiopharmaInnovation #CrossFunctionalCollaboration

https://bit.ly/3XBmcDg 💡 From Traditional to Innovative: How Eli Lilly and Company Fast-Tracked Its Insights On Oct. 1, hear from Shellie Miller (Eli Lilly) and Shannon Childs (Sago) about how Eli Lilly redefined its approach to market research through tech, strategic partnerships, and enhanced recruitment. If you're aiming for speed and quality in your research, this session is for you! 🎯 Register now for Sago Vision '25: https://bit.ly/3MOU76K #MarketResearch #MRX #InsightsIndustry #SagoVision25

It’s interesting that the longer you work for an organization the more your perspective becomes internally focused. And you have to be intentional about keeping up with the external landscape. I do that by reading trade publications and thought pieces on industry trends, while also making it a point to attend a few conferences every year and continue to grow–and connect with–my external network. In doing my reading, I recently came across a McKinsey & Company article noting that competition in biopharma is more intense, diverse, and complex than ever. It reflects what we’re feeling at Genentech and why our new mantra is “Evolution is Essential.” It’s worth reading. I’d love to hear what you do to keep your external perspective.

As this year's JP Morgan healthcare week is behind us, the time has come for life science professionals to set their sights on next year's event. 🔍 Discover why attending JP Morgan should be a top priority for Swedish companies and learn from the experiences of Evelina Vågesjö from ILYA Pharma, Anne-Marie Wenthzel from Sprint Bioscience and SwedenBIOs Marjo Puumalainen who have attended JP Morgan in the past. 💡 Find out how SwedenBIO supports member companies during the bustling week, from discounted access to partnering conferences to invaluable meeting facilities. 📝 Read the article here: https://lnkd.in/dStdUjG2 #JPmorganHealthcareWeek #LifeScienceProfessionals #Networking #Partnerships #GlobalOpportunities #IndustryGrowth